Application of effective components of guava fruits in eye protection

Abstract

The invention provides application of effective components of guava fruits in eye protection, and belongs to the technical field of biological medicine. The invention provides an application of effective components of guava fruits in preparation of eye protection medicines, an application in preparation of medicines for treating retina light injury and an application in preparation of medicines for inhibiting apoptosis of eye cells. According to the embodiment of the invention, a zebra fish blue light eye injury model and a mouse retina light injury model are constructed and treated by using the effective components of the guava fruits, and the effective components of the guava fruits are found to have a protective effect on eye cell apoptosis, retina injury and the like, and the protective effect of the effective components is equivalent to that of xanthophyll.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of effective ingredients of guava fruit in eye protection. Background Art

[0002] Eye health is an important part of national health, involving people of all ages throughout their lives. However, as electronic products gradually penetrate people's lives, excessive use of eyes has become the norm, troubling people from children to the elderly. Myopia problems in children and adolescents, high blue light exposure problems in young and middle-aged people, and macular degeneration problems in the elderly are all related to varying degrees of retinal light damage. In particular, age-related macular degeneration (AMD) is a difficult-to-treat disease that seriously damages vision and is one of the leading causes of blindness in adults over 50 years old worldwide. With the aging of the population, the incidence of AMD is also increasing year by year. It is estimated that the number of AMD patients worldwide will reach 288 million by 2040, and there is currently no clinically effective drug treatment plan except for anti-VEGF drugs. It can be seen that related retinal diseases and even visual impairment caused by retinal light damage have a very serious impact on the physical and mental health and quality of life of the people, and increase the burden on families and society. Therefore, preventing retinal light damage and promoting visual health have become important issues that need to be solved urgently. Summary of the invention

[0003] The purpose of the present invention is to provide an application of the active ingredients of guava fruit in eye protection, and for the first time propose that the active ingredients of guava fruit have a protective effect on retinal light damage, and can be used in the development of functional products such as drugs for treating retinal light damage diseases and relieving visual fatigue.

[0004] The invention provides application of effective components of guava fruit in preparing eye-protecting medicine.

[0005] The present invention also provides the use of the effective components of guava fruit in preparing medicine for treating retinal light damage.

[0006] The present invention also provides the use of the effective components of guava fruit in preparing a medicine for inhibiting apoptosis of eye cells.

[0007] The present invention also provides the use of effective ingredients of guava fruit in preparing functional food for alleviating visual fatigue.

[0008] Preferably, the effective ingredients of guava fruit include water extract of guava fruit and / or dried guava juice.

[0009] The invention also provides an eye protection medicine, comprising the effective ingredients of guava fruit and pharmaceutically acceptable auxiliary materials.

[0010] The present invention also provides a drug for treating retinal light damage, which comprises the active ingredients of guava fruits and pharmaceutically acceptable excipients.

[0011] The present invention also provides a functional food for relieving visual fatigue, which comprises the active ingredients of guava fruits and food-acceptable excipients.

[0012] Beneficial effects: The present invention provides the application of the active ingredients of guava fruits in the preparation of drugs for protecting eyes. In the examples, by constructing a zebrafish blue light eye damage model and a mouse retinal light damage model, and treating them with the active ingredients of guava fruits, it is found that the active ingredients of guava fruits have a protective effect on ocular cell apoptosis, retinal damage, etc., and its protective effect is equivalent to that of lutein. Description of the Drawings

[0013] Figure 1 It is a typical diagram of the fluorescence intensity of apoptotic cells in the eyes of zebrafish after treatment with guava extract and lutein; the green fluorescent particles indicated by the yellow arrows in the figure are apoptotic cells;

[0014] Figure 2 It is a quantitative diagram of the fluorescence intensity of apoptotic cells in the eyes of zebrafish after treatment with guava extract and lutein; in the figure, ***P < 0.001; # P < 0.05; ## P < 0.01; ### P < 0.001; * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different administration groups and the model group;

[0015] Figure 3 It is a H&E staining diagram of mouse retina; in the figure, A represents the H&E staining diagram of mouse retina tissue and the thickness diagrams of the outer nuclear layer and inner nuclear layer of the retina, scale bar: 500μm and 50μm; B and C represent the quantitative diagrams of the thickness of the outer nuclear layer and inner nuclear layer of the retina, the number of mice (n = 4 - 6); in the figure, ***P < 0.001; ****P < 0.0001; ## P < 0.01, * indicates the statistical difference between the model group and the normal control group, # indicates the statistical difference between different administration groups and the model group, and ns indicates no significant difference compared with the model group;

[0016] Figure 4 It is a TUNEL staining diagram of apoptotic cells in mouse retina; in the figure, A represents the TUNEL fluorescence staining diagram of mouse retina, DAPI blue fluorescence represents the cell nucleus, and TUNEL red fluorescence represents apoptotic cells, scale bar: 500μm and 200μm; B represents the quantitative diagram of the fluorescence intensity of apoptotic cells in the retina, the number of mice (n = 4 - 6), in the figure, **P < 0.01; # P < 0.05;## P < 0.01. * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different drug administration groups and the model group.

[0017] Figure 5 It is a graph of the protein expression level in the mouse retina tissue; in the figure, A represents the Western blot detection graph of the expression of anti-apoptotic protein Bcl-2 and internal reference GAPDH protein; B represents the quantitative graph of Bcl-2 protein expression, and the number of mice (n = 3); in the figure, *P < 0.05. ## P < 0.01. * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different drug administration groups and the model group.

[0018] Figure 6 It is a graph of the malondialdehyde content in mouse plasma, and the number of mice (n = 12); in the figure, **P < 0.01. ## P < 0.01. * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different drug administration groups and the model group. Detailed implementation manners

[0019] The present invention provides the application of the active ingredients of guava fruits in the preparation of eye-protecting drugs.

[0020] The active ingredients of the guava fruits described in the present invention preferably include the extract of guava fruits and / or the dried product of guava juice, and the extraction solvent of the extract preferably includes water. The present invention has no special limitation on the source of the water extraction of the guava fruits, and it can be extracted by oneself, such as combining the filtrates after three water extractions, and then filtering, concentrating and spray-drying to obtain it, or it can be purchased. In the examples, it is preferably to use the guava extract purchased from Chengdu Mansite Biotechnology Co., Ltd. (extracted from guava fruits with water, yellow powder) for experiments. And the commercially available guava extract is obtained by spray-drying, so maltodextrin is added during spray-drying to promote powder formation, and the mass content of maltodextrin in the dried yellow powder product is 25%. However, when specifically used, it is calculated according to the dosage of the pure guava water extraction excluding maltodextrin. For example, for a commercially available guava extract with a dosage of 250 μg / mL, it is counted as 188 μg / mL of guava extract. The dried product of the guava juice described in the present invention preferably includes guava juice powder, and more preferably includes the product prepared by directly spray-drying the filtered guava fruit juice.

[0021] In the present invention, the zebrafish blue light eye injury model is characterized by apoptosis of ocular cells. After treatment with guava extracts at different concentrations, the apoptosis of zebrafish ocular cells can be significantly reduced, indicating that guava extracts have the eye protection effect of resisting blue light injury to the eyes. When the guava extracts are administered to the mouse retinal light injury model under light conditions, the morphological changes of the outer nuclear layer and inner nuclear layer of the retina can be well improved, and the thickness of the outer nuclear layer and inner nuclear layer is increased, indicating that guava extracts have a good effect on improving retinal light injury.

[0022] The present invention also provides the use of the active ingredients of guava fruits in the preparation of a drug for treating retinal light injury.

[0023] The use described in the present invention is preferably the same as above and will not be elaborated here.

[0024] The present invention also provides the use of the active ingredients of guava fruits in the preparation of a drug for inhibiting apoptosis of ocular cells.

[0025] The active ingredients of guava fruits described in the present invention preferably include the water extract of guava fruits and / or the dried product of guava juice, which is the same as above and will not be elaborated here.

[0026] The present invention also provides an eye protection drug, which includes the active ingredients of guava fruits and pharmaceutically acceptable excipients.

[0027] The present invention also provides a drug for treating retinal light injury, which includes the active ingredients of guava fruits and pharmaceutically acceptable excipients.

[0028] The present invention does not particularly limit the dosage form of the drug, and it can be prepared using conventional dosage forms in the art.

[0029] The present invention also provides the use of the active ingredients of guava fruits in the preparation of a functional food for relieving visual fatigue.

[0030] The functional foods referred to in the present invention preferably include: 1) ordinary foods that have been experimentally proven to have the function of regulating the body's physiological functions and enhancing the body's health but cannot be classified as health foods; 2) health foods that have health care functions such as being able to improve the body's health status.

[0031] The present invention also provides a functional food for relieving visual fatigue, which includes the following active ingredients of guava fruits and food-acceptable excipients.

[0032] The present invention does not particularly limit the type of the functional food, such as eye protection gel gummies, chewable tablets, (soft) capsules, solid tablets or oral liquids, etc.

[0033] To further illustrate the present invention, the application of the active ingredients of guava fruits provided by the present invention in eye protection will be described in detail below in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0034] In Example 1 of the present invention, the results of data statistical processing are expressed as mean±SE. Statistical analysis was performed using SPSS 26.0 software, and p<0.05 indicates that the difference is statistically significant.

[0035] In Example 2 of the present invention, Prism 8 software was used for drawing statistical charts and statistical analysis of the data. All data are expressed as mean±standard error. The difference between two groups was analyzed by independent sample t-tests, and P<0.05 indicates that the difference is statistically significant.

[0036] Example 1

[0037] The zebrafish experiment was commissioned to Hangzhou Huante Biotechnology Co., Ltd. (Project No.: 9037).

[0038] 1. Experimental method:

[0039] 1.1 Experimental animals

[0040] The zebrafish were all raised in fish culture water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450 - 550 μS / cm; the pH was 6.5 - 8.5; the hardness was 50 - 100 mg / L CaCO3). They were provided by the fish culture center of Huante Biotechnology Co., Ltd. The license number for the use of experimental animals is: SYXK(Zhe)2022 - 0004. The feeding management meets the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethical review number is: IACUC - 2024 - 9037 - 01.

[0041] 1.2 Instruments, consumables and reagents

[0042] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); Ultra-pure water machine (EPED-S2-30D, Nanjing Yipuyida Technology Co., Ltd., China); Blue light instrument (50w450nm, China); Biochemical incubator (SPX-250B-Z, Shanghai Boxun Medical Biological Instrument Co., Ltd., China); Electric focusing continuous zoom fluorescence microscope (AZ100, Nikon, Japan); 6-well plate (batch number DB1000305, Zhejiang Beilanbo Biotechnology Co., Ltd., China); 0.22 μM disposable needle filter (batch number 23214867, Biosharp, China).

[0043] Pronase E (batch number G12511Y118034, Shanghai Yuanye Bio-Technology Co., Ltd., China); Dimethyl sulfoxide (DMSO, batch number BCCD8942, Sigma, Switzerland); Methyl cellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Acridine orange (AO, batch number C12894919, Shanghai Macklin Biochemical Co., Ltd., China); Lutein (batch number A2316085, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0044] Guava extract was dissolved in ultrapure water. Lutein was dissolved in DMSO, and the dosage for zebrafish was 62.5 μg / mL.

[0045] 1.3 Determination of the maximum test concentration (MTC)

[0046] Wild-type AB strain zebrafish at 1 day post-fertilization (1 dpf) were randomly selected for blue light irradiation after hatching to establish a zebrafish blue light eye injury model. At 3 dpf, model zebrafish with good developmental status were randomly selected and distributed into 6-well plates, with 30 zebrafish in each well (experimental group). Different concentrations of guava extract were administered by water solution (the concentrations are shown in Table 1). At the same time, a normal control group and a model group were set up, and the volume of each well was 3 mL. After treatment at 28 °C for 1 day, the MTC of guava extract on model zebrafish was determined.

[0047] As shown in Table 1, the MTC of guava extract against blue light eye protection in zebrafish was 375 μg / mL.

[0048] Table 1 Results of the concentration exploration experiment of guava extract for anti-blue light eye protection (n = 30)

[0049]

[0050]

[0051] 1.4 Evaluation of the anti - blue - light eye - protection effect

[0052] Wild - type AB - strain zebrafish at 1 dpf were randomly selected after hatching and irradiated with blue light to establish a zebrafish blue - light eye injury model. At 3 dpf, model zebrafish with good developmental status were randomly selected and distributed into 6 - well plates, with 30 zebrafish in each well (experimental group). Different concentrations of guava extract (concentrations are shown in Table 2) were administered by dissolving in water, and lutein at a concentration of 62.5 μg / mL was used as the positive control. At the same time, a normal control group and a model group were set up, and the volume of each well was 3 mL. After treatment at 28 °C for 1 day, the zebrafish in each experimental group were stained with AO in the dark for 30 min. After washing 3 times with standard dilution water, 10 zebrafish were randomly selected from each experimental group and placed under a fluorescence microscope for photographing. Data were analyzed and collected using Image J software, and the fluorescence intensity of apoptotic cells in the zebrafish eyes was analyzed and statistically analyzed. The anti - blue - light eye - protection effect of guava extract was evaluated based on the statistical analysis results of the above - mentioned indicators.

[0053] The results are as Figures 1 - 2 shown in Table 2. The zebrafish blue - light eye injury model showed apoptosis of eye cells. After treatment with different concentrations of guava extract, the apoptosis of eye cells in zebrafish could be significantly reduced, indicating that guava extract has the eye - protection effect of resisting blue - light damage to the eyes.

[0054] Table 2 Experimental results of the evaluation of the anti - blue - light eye - protection effect of guava extract (n = 10)

[0055]

[0056] Example 2

[0057] 2. Experimental methods

[0058] 2.1 Experimental animals

[0059] 8 - week - old male BALB / c mice were purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd. Before the start of the experiment, all mice were adaptively fed under a 12:12 h light / dark cycle in an animal room at a certain temperature and humidity for 1 week, and normal food and drinking water were provided every day. All experimental operations followed the guidelines for animal care and use of the Animal Research Institute of Zhejiang University.

[0060] 2.2 Construction of the mouse light - injury model

[0061] A self-made light box with a length of 108 cm, a width of 50 cm, and a height of 72 cm was used. The light intensity was detected by a lux meter to be 8500 - 10000 Lux. After eye examination of the mice, 60 mice with normal eyes were randomly divided into a control group, a model group, a lutein group (100 mg / kg), a low-dose guava extract group (75 mg / kg), and a high-dose guava extract group (150 mg / kg), with 12 mice in each group. Lutein and guava extract were suspended in a 5% sodium carboxymethylcellulose (CMC-Na) solution and administered by gavage once a day. Mice in the blank and model groups were gavaged with an equal volume of 5% CMC-Na. Administration was continued for 10 days. After 10 days, the mice in the model group, lutein group, low-dose guava extract group, and high-dose guava extract group were dark-treated for 36 h, then atropine ophthalmic gel was applied to both eyes of the mice to dilate the pupils. The mice were placed in a self-made light device with a light intensity of 8000 - 10000 Lux (the blank group was raised in a normal environment) and given continuous light for 24 h. After the light exposure ended, blood was collected by enucleating the eyes of each group of mice, and the eye tissues were collected for subsequent relevant tests of the experiment.

[0062] 2.3 Experimental Instruments

[0063] Table 3 Instruments involved in Example 2

[0064]

[0065] 2.4 Experimental Consumables and Reagents

[0066] Table 4 Consumables used in the experiment of Example 2

[0067]

[0068]

[0069] 2.5 Histopathological Detection

[0070] For each group, 6 mouse eye tissues were taken for hematoxylin-eosin staining (HE) and TUNEL fluorescence staining of apoptotic cells, and the histopathological changes of the mouse eye tissues were observed using an optical microscope (completed by Wuhan Saiweier Biotechnology Co., Ltd.).

[0071] 2.5.1 Experimental Procedures for H&E Staining

[0072] (1) Dewax the paraffin sections to water: sequentially place the sections in environmental protection type dewaxing solution Ⅰ for 20 min - environmental protection type dewaxing solution Ⅱ for 20 min - absolute ethanol Ⅰ for 5 min - absolute ethanol Ⅱ for 5 min - 75% alcohol for 5 min, and wash with tap water.

[0073] (2) Pretreatment: The sections were treated with hematoxylin-eosin (H&E) high-definition permanent staining solution for 1 min.

[0074] (3) Hematoxylin staining: Stain the sections with hematoxylin solution for 3-5 min, wash with tap water, differentiate with differentiation solution, wash with tap water, reblue with bluing solution, and rinse with running water.

[0075] (4) Eosin staining: Dehydrate the sections in 95% gradient alcohol for 1 min and then stain them in eosin solution for 15 s.

[0076] (5) Dehydration and sealing: The sections were placed in anhydrous ethanol I for 2 min, anhydrous ethanol II for 2 min, anhydrous ethanol III for 2 min, n-butanol I for 2 min, n-butanol II for 2 min, xylene I for 2 min, and xylene II for 2 min, and then sealed with transparent neutral gum.

[0077] (6) Microscope examination, image acquisition and analysis.

[0078] The results of retinal H&E staining are as follows Figure 3 As shown in the figure, light damage caused the outer nuclear layer and inner nuclear layer of the retina of the model group mice to become loose and thin, indicating that light damage caused retinal cells ( Figure 3 In the middle A). However, both low-dose and high-dose guava extracts given under light conditions can significantly improve the morphological changes of the outer nuclear layer and inner nuclear layer of the retina, and increase the thickness of the outer nuclear layer and inner nuclear layer ( Figure 3 BC), indicating that guava extract has a good effect in improving retinal light damage. And compared with the positive drug lutein, guava extract has the same anti-light damage eye protection effect as lutein.

[0079] 2.5.2 TUNEL staining experimental steps

[0080] (a) Dewaxing of paraffin sections: sequentially place the sections in environmentally friendly dewaxing solution I for 10 min - environmentally friendly dewaxing solution II for 10 min - environmentally friendly dewaxing solution I and II for 10 min - anhydrous ethanol I for 5 min - anhydrous ethanol II for 5 min - anhydrous ethanol III for 5 min - and wash with distilled water.

[0081] (b) Proteinase K repair: After the slices are slightly dried, use a tissue pen to draw a circle around the tissue (to prevent the liquid from flowing away), add proteinase K working solution to the circle to cover the tissue, and incubate in a 37°C incubator for 20 minutes. Place the slide in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, each time for 5 minutes. (Protease K working solution preparation method, stock solution: PBS = 1:9).

[0082] (c) Membrane permeabilization: After the slices are slightly dried, drip the membrane permeabilization working solution into the circle to cover the tissue, incubate at room temperature for 20 minutes, place the slides in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, each time for 5 minutes. (The membrane permeabilization solution is 0.1% triton. The preparation method is triton stock solution: PBS = 1:1000).

[0083] (d) Room temperature equilibrium: After the slices are slightly dried, add buffer to cover the tissue and incubate the buffer at room temperature for 10 min.

[0084] (e) Add reaction solution: according to the number of slices and tissue size, take an appropriate amount of TDT enzyme, dUTP, and buffer in the tunel kit and mix them in a ratio of 1:5:50. Add them to the circle to cover the tissue. Place the slices flat in a humidified box and incubate them in a constant temperature box at 37°C for 1 hour. Add a small amount of water to the humidified box to maintain humidity.

[0085] (f) DAPI counterstaining of cell nuclei: The sections were washed three times with PBS (pH 7.4), 5 min each time. After removing the PBS, DAPI staining solution was added dropwise into the circle and incubated at room temperature for 10 min in the dark.

[0086] (g) Sealing: Place the slides in PBS (pH 7.4) and wash them on a decolorizing shaker for 3 times, 5 min each time. After the sections are slightly dried, seal them with an anti-fluorescence quenching sealing medium.

[0087] (h) Microscopic examination and photography: The sections were observed and images were collected under a fluorescence microscope. (DAPI has an ultraviolet excitation wavelength of 330-380 nm, an emission wavelength of 420 nm, and emits blue light; TMR has an excitation wavelength of 510-561 nm, and an emission wavelength of 590 nm, and emits red light.

[0088] (i) Interpretation of Tunel red fluorescence results: The cell nuclei stained with DAPI are blue under ultraviolet excitation. The Tunel kit is labeled with TMR fluorescein, and the positive apoptotic cell nuclei are red.

[0089] The results of TUNEL fluorescence staining of apoptotic cells in retinal tissue are as follows Figure 4 As shown, light induced a large number of apoptosis in the retinal cells of the model group mice (red fluorescence, Figure 4 A), while both low and high doses of guava extract can effectively improve retinal cell apoptosis caused by light exposure ( Figure 4 In B), the protective effect of guava extract on retinal cell apoptosis is comparable to that of the positive drug lutein.

[0090] 1.6 Western Blot detection of related protein expression levels

[0091] Take the mouse retina, add 100-150 μL of RIPA lysis buffer for every 10 mg of tissue, and use the BCA protein quantification kit to detect the protein content after sufficient lysis. Add an appropriate amount of loading buffer to the protein lysis buffer and heat at 95°C for 10 minutes to prepare the protein loading sample. Add an appropriate amount of sample to 10% SDS-PAGE gel, transfer to PVDF membrane after electrophoresis. After the transfer, use 5% skim milk to block at room temperature for 1 hour, then add the corresponding primary antibody and incubate overnight in a 4°C refrigerator. After incubating the membrane with the secondary antibody of the corresponding species at room temperature for 1 hour, develop it in a red laser two-color imaging system, use the red laser two-color imaging system supporting software for band analysis, and use GAPDH protein expression as an internal reference.

[0092] Retinal tissue was peeled off from mouse eyeballs to prepare protein samples. The expression of anti-apoptotic protein Bcl-2 in retinal tissue was determined by Western blot. Figure 5 As shown in the results, light exposure caused a significant decrease in the expression of anti-apoptotic protein Bcl-2 in the retinal tissue of the model group mice, while high-dose guava extract significantly increased the expression of anti-apoptotic protein Bcl-2 in the retinal tissue. GAPDH was used as an internal reference for protein expression ( Figure 5 The results suggest that guava extract can protect retinal cells from light-induced apoptosis by increasing the expression of anti-apoptotic proteins.

[0093] 2.7 Determination of plasma MDA levels in mice

[0094] The mouse blood was collected in an anticoagulant tube, centrifuged at 3000 RPM for 10 min at 4°C, and the upper plasma was collected. The MDA content was determined according to the method provided by the kit manufacturer.

[0095] Plasma malondialdehyde (MDA) is one of the main products of cell membrane lipid peroxidation. Its content can be used as an indicator of lipid peroxidation to reflect the degree of cell membrane lipid peroxidation. Figure 6 As shown, light exposure caused an increase in the level of lipid peroxidation in the model group mice, while high-dose guava extract could significantly reduce the level of lipid peroxidation in the body, indicating that guava extract has a protective effect on cellular oxidative stress damage.

[0096] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of the active ingredients of guava fruits in the preparation of eye-protecting drugs.

2. Use of the active ingredients of guava fruits in the preparation of drugs for treating retinal light damage.

3. Use of the active ingredients of guava fruits in the preparation of drugs for inhibiting apoptosis of eye cells.

4. Use of the active ingredients of guava fruits in the preparation of functional foods for relieving visual fatigue.

5. The application according to any one of claims 1 to 4, characterized in that The active ingredients of the guava fruits include the aqueous extract of guava fruits and / or the dried product of guava juice.

6. A drug for protecting eyesight, characterized in that, It includes the active ingredients of guava fruits and pharmaceutically acceptable excipients.

7. A drug for treating retinal light damage, characterized in that, It includes the active ingredients of guava fruits and pharmaceutically acceptable excipients.

8. A functional food for relieving visual fatigue, characterized in that, It includes the active ingredients of guava fruits and food-acceptable excipients.

Images